This company listing is no longer active
Medlab Clinical Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Medlab Clinical's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 19.6% annually. Revenues have been declining at an average rate of 19.2% per year.
Wichtige Informationen
-18.9%
Wachstumsrate der Gewinne
-7.9%
EPS-Wachstumsrate
Biotechs Wachstum der Industrie | 9.6% |
Wachstumsrate der Einnahmen | -19.2% |
Eigenkapitalrendite | -108.3% |
Netto-Marge | -541.7% |
Letzte Ertragsaktualisierung | 30 Jun 2022 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now
Oct 06Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?
Oct 05What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay
Feb 21Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years
Dec 30Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future
Nov 22Aufschlüsselung der Einnahmen und Ausgaben
Wie Medlab Clinical Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Jun 22 | 2 | -8 | 12 | 2 |
31 Mar 22 | 1 | -9 | 9 | 1 |
31 Dec 21 | 4 | -12 | 11 | 1 |
30 Sep 21 | 4 | -12 | 11 | 2 |
30 Jun 21 | 1 | -10 | 11 | 2 |
31 Mar 21 | 1 | -10 | 10 | 2 |
31 Dec 20 | 1 | -11 | 9 | 2 |
30 Sep 20 | 2 | -12 | 9 | 2 |
30 Jun 20 | 3 | -13 | 10 | 2 |
31 Mar 20 | 4 | -12 | 10 | 2 |
31 Dec 19 | 4 | -12 | 11 | 2 |
30 Sep 19 | 5 | -10 | 10 | 1 |
30 Jun 19 | 5 | -8 | 10 | 1 |
31 Mar 19 | 5 | -7 | 8 | 1 |
31 Dec 18 | 5 | -6 | 7 | 0 |
30 Sep 18 | 4 | -5 | 7 | 0 |
30 Jun 18 | 4 | -5 | 6 | 0 |
31 Mar 18 | 4 | -4 | 6 | 0 |
31 Dec 17 | 5 | -4 | 6 | 0 |
30 Sep 17 | 5 | -4 | 5 | 0 |
30 Jun 17 | 4 | -4 | 5 | 0 |
31 Mar 17 | 4 | -4 | 5 | 0 |
31 Dec 16 | 4 | -4 | 4 | 0 |
30 Sep 16 | 3 | -4 | 4 | 0 |
30 Jun 16 | 3 | -3 | 4 | 0 |
Qualität der Erträge: MDC is currently unprofitable.
Wachsende Gewinnspanne: MDC is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Beschleunigtes Wachstum: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.2%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: MDC has a negative Return on Equity (-108.25%), as it is currently unprofitable.